论文部分内容阅读
目的探讨缬沙坦联合黄芪注射液治疗早期糖尿病肾病(DN)的疗效及机制。方法选择早期DN患者56例,随机分为治疗组和对照组,各28例。两组均给予胰岛素控制血糖及缬沙坦80 mg/d;治疗组加用黄芪注射液静滴。比较两组尿蛋白排泄率(UAER)、尿β2微球蛋白(β2-MG)、血压、空腹血糖、血肌酐(SCr)、尿素氮(BUN)、总胆固醇(TG)、甘油三酯(TC)的变化。结果治疗后两组UAER、β2-MG明显下降,且治疗组下降优于对照组(P<0.05)。血压、血糖治疗后明显下降,但两组治疗后比较无统计学意义(P>0.05)。BUN、SCr对照组治疗前后比较差异无统计学意义(P>0.05),而治疗组治疗前后比较差异有统计学意义(P<0.05)。结论缬沙坦联合黄芪注射液治疗早期糖尿病肾病疗效显著,可有效控制和延缓DN的发展。
Objective To investigate the efficacy and mechanism of valsartan combined with astragalus injection in the treatment of early diabetic nephropathy (DN). Methods 56 patients with early DN were selected and randomly divided into treatment group and control group, with 28 cases in each group. Both groups were given insulin control of blood glucose and valsartan 80 mg / d; treatment group with Astragalus injection intravenous infusion. The urinary protein excretion rate (UAER), urinary β2 microglobulin (β2-MG), blood pressure, fasting blood glucose, serum creatinine (SCr), blood urea nitrogen (BUN), total cholesterol (TG), triglyceride )The change. Results After treatment, the levels of UAER and β2-MG were significantly decreased in both groups, and the treatment group was better than the control group (P <0.05). Blood pressure, blood glucose decreased significantly after treatment, but there was no significant difference between the two groups after treatment (P> 0.05). There was no significant difference between BUN and SCr before and after treatment (P> 0.05), while the difference between before and after treatment in the treatment group was statistically significant (P <0.05). Conclusion Valsartan combined with astragalus injection in the treatment of early diabetic nephropathy significant effect, which can effectively control and delay the development of DN.